Prediction and clinical utility of a contralateral breast cancer risk model
Daniele Giardiello(University of Milano-Bicocca), Laura J. van’t Veer(University of California, San Francisco), Iris Kramer(The Netherlands Cancer Institute), Peter A. Fasching(Universitätsklinikum Erlangen), William Tapper(University of Southampton), Jenny Chang‐Claude(Universität Hamburg), Annika Lindblom(Karolinska University Hospital), Jan Lubiński(Tumour Institute of Tuscany), Jonine D. Figueroa, Flora E. van Leeuwen(The Netherlands Cancer Institute), Rob A.�E.�M. Tollenaar(Leiden University Medical Center), Alison M. Dunning(University of Cambridge), Kamila Czene(Karolinska Institutet), Carolien H. M. van Deurzen(Erasmus MC), Michael Hauptmann(Medizinische Hochschule Brandenburg Theodor Fontane), Peter Devilee(Leiden University), Saskia Pelders(Erasmus MC Cancer Institute), Douglas F. Easton(University of Cambridge), Loı̈c Le Marchand(University of Hawaiʻi at Mānoa), Per Hall(Karolinska Institutet), Alexandra J. van den Broek(The Netherlands Cancer Institute), Anna Jakubowska(Pomeranian Medical University), Delal Akdeniz(Erasmus MC Cancer Institute), Heli Nevanlinna(University of Helsinki), Carl Blomqvist(University of Helsinki), Agnes Jager(Erasmus MC Cancer Institute), Ute Hamann(German Cancer Research Center), Audrey Jung(German Cancer Research Center), Mitul Shah(University of Cambridge), Stig E. Bojesen(University of Copenhagen), Sabine Siesling(Netherlands Comprehensive Cancer Organisation), Chantal Van Ongeval(KU Leuven), Renske Keeman(The Netherlands Cancer Institute), Montserrat García‐Closas(Institute of Cancer Research), Diether Lambrechts(VIB-KU Leuven Center for Cancer Biology), Muriel A. Adank(The Netherlands Cancer Institute), Paul D.P. Pharoah(Cedars-Sinai Medical Center), Melissa C. Southey(The University of Melbourne), Luigi Mariani(Fondazione IRCCS Istituto Nazionale dei Tumori), Vincent T.H.B.M. Smit(Leiden University Medical Center), Ewout W. Steyerberg(Erasmus MC), Christopher A. Haiman(University of Southern California), John L. Hopper(The University of Melbourne), Mehdi Manoochehri(German Cancer Research Center), Henrik Flyger(Herlev Hospital), Manjeet K. Bolla(University of Cambridge), Hester S. A. Oldenburg(The Netherlands Cancer Institute), Lothar Haeberle(Friedrich-Alexander-Universität Erlangen-Nürnberg), Mariël Brinkhuis(Leiden University Medical Center)
Cited by 40
Related Papers
Assessing the Performance of Prediction Models
|Epidemiology|2009|4.9k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.3k
Current and future burden of breast cancer: Global statistics for 2020 and 2040
|The Breast|2022|3.3k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k